1200 Pharma uses breakthrough medicinal chemistry technology from Caltech and proprietary biomarker driven assays from UCLA to dramatically accelerate pre-clinical drug discovery and clinical approval timelines.
Our Portfolio
Some of the Companies We've Backed
3D Bio Corporation is shaping possibilities – to print what the body cannot heal. 3D Bio seeks a world in which healthy living tissue is no longer in short supply, and to open new paradigms for surgically healing patients.
Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV.
Amorphology is using novel metal alloy technologies and production techniques, to create specialty gears for non-commercial robotics applications.
Applaud Medical was established to develop an innovative new treatment for kidney stones, a condition diagnosed in more than 2 million individuals in the U.S. every year.
Auspion is a groundbreaking wireless power company that incorporates power transmission, data transmission and sensing in a single transmitter and corresponding receiver chip.
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders.
Behavioral Signals provides award-winning emotion recognition and behavioral analytics technology based on a decade of research in cognitive modeling and advanced machine learning algorithms at the University of Southern California’s SAIL lab.
Chimera Bioengineering is a biotherapeutics company focused on building RNA based gene regulatory systems for chimeric antigen receptor (CAR) T cell therapeutics with greater efficacy against solid tumors and superior safety.
Compellon revolutionizes the modern approach to predictive analytics by delivering unprecedented speed and ease in knowledge discovery and model building.
DEARhealth is a health tech startup that provides a SaaS technology platform which uses advanced data analytics to drive disease-specific, coordinated care pathways with streamlined provider workflows, patient apps and organizational decision support.
Delpor develops the next generation Drug Delivery Systems which improve the clinical and commercial value of new and existing drugs and biopharmaceuticals.
Foldax is developing synthetic heart valves with the goal of delivering non-thrombogenic aortic and mitral valves at dramatically lower costs to existing artificial or tissue valves.
Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.
Holoclara is an immunotherapy startup that aims to bring relief to people suffering from autoimmune disorders through the delivery of nematode derived molecules with potent therapeutic properties.
Keren Therapeutics is taking a metabolic and endocrine approach to restoring muscle function and age-related cognitive decline.
KMLabs is the leading provider of the world’s most advanced femtosecond lasers, claiming the top universities and research institutions worldwide as its customers.
LifeSprout is a seed-stage biotechnology company dedicated to developing the next-generation of injectable soft tissue restoration products including nanofiber-hydrogel subdermal fillers and cell and drug delivery scaffolds.
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents that modulate cellular differentiation for the treatment of cancer and disorders of pigmentation.
MemiRay is a personal health monitoring device development organization with a novel approach to personal chemistry.
MemVerge aims to offer the software that will allow seamless convergence of main computer memory and main computer storage using a single pool of non volatile RAM memory.
MixComm is a fabless semiconductor company developing transformative solutions for emerging wireless applications and markets.
NanoClear Technologies has a proprietary process that can alter wettability of any arbitrary surface. The primary application of the technology is to provide anti-fogging capabilities in consumer wearables and anti-frost performance in a variety of industrial applications.
Neuro-Bio is an early stage biopharmaceutical company focused on developing novel, effective therapeutics for neurodegenerative disorders including Alzheimer’s, Parkinson’s and Motor Neuron Diseases.
nFugue is pioneering a new concept to produce large-scale nano-architected materials that could be used in a wide variety of applications.
Opera Therapeutics is developing next-generation treatments for ocular and neurological diseases.
A Water Planet company, PolyCera Membranes develops and markets next-generation membrane technology for industrial wastewater treatment and process separation, setting new standards in performance and total cost of ownership.
Provivi’s mission is to provide disruptive chemistry solutions for agricultural, household, and professional pest control that are safe and environmentally benign.
Repairogen is pursuing potent, robust, naturally-derived, small-molecule active ingredients for cosmetics, providing powerful anti-aging effects by enhancing DNA repair activity in skin cells and reducing the risk of skin cancer.
Sienza Energy is exploring a radical new 3D nanostructured electrode design for batteries that has the promise to improve the performance of a wide range of battery driven devices.
Symbiotix Biotherapies, Inc. is a pioneering microbiome company developing novel molecular therapeutics based on molecules derived from the human microbiome.
Tanvas’ surface haptics lets you feel what you see on any touchscreen. Software control of the tactile experience creates a new level of usability and multisensory engagement.
Transient Plasma Systems (TPS) engineers pulsed power systems as an enabling technology for commercial, industrial, and research applications across a broad range of areas including combustion, bio-electrics, and agriculture.